Research graph
References from CASynergy: A causal attention model for interpretable prediction of cancer drug synergy. Local targets link to admitted publications; unresolved targets remain external evidence.
Cell cycle-mediated drug resistance: an emerging concept in cancer therapy
2001 · External reference
Computational methods in drug discovery
10.1124/pr.112.007336 · 2013 · External reference
Support-Vector Networks
10.1023/a:1022627411411 · 1995 · External reference
Random forests
10.1023/a:1010933404324 · 2001 · External reference
Unresolved reference
2006 · External reference
Unresolved reference
2020 · External reference
Machine learning approaches for drug combination therapies
2021 · External reference
DeepSynergy: predicting anti-cancer drug synergy with Deep Learning
10.1093/bioinformatics/btx806 · 2018 · External reference
Deep learning for predicting synergistic drug combinations: State‐of‐the‐arts and future directions
10.1002/ctd2.317 · 2024 · External reference
Semi-supervised classification with graph convolutional networks
2016 · External reference
Knowledge graphs: New directions for knowledge representation on the semantic web (dagstuhl seminar 18371)
2019 · External reference
GraphSynergy: a network-inspired deep learning model for anticancer drug combination prediction
10.1093/jamia/ocab162 · 2021 · External reference
KGANSynergy: knowledge graph attention network for drug synergy prediction
10.1093/bib/bbad167 · 2023 · External reference
Multi-way relation-enhanced hypergraph representation learning for anti-cancer drug synergy prediction
10.1093/bioinformatics/btac579 · 2022 · External reference
Predicting cell line-specific synergistic drug combinations through a relational graph convolutional network with attention mechanism
10.1093/bib/bbac403 · 2022 · External reference
Unresolved reference
2022 · External reference
DeepDDS: deep graph neural network with attention mechanism to predict synergistic drug combinations
10.1093/bib/bbab390 · 2022 · External reference
Targeting Metabolic Reprogramming to Improve Breast Cancer Treatment: An In Vitro Evaluation of Selected Metabolic Inhibitors Using a Metabolomic Approach
10.3390/metabo11080556 · 2021 · External reference
Gene Set Knowledge Discovery with Enrichr
2021 · External reference
Combined treatment with ruxolitinib and MK-2206 inhibits the JAK2/STAT5 and PI3K/AKT pathways via apoptosis in MDA-MB-231 breast cancer cell line
10.1007/s11033-022-08034-4 · 2023 · External reference
The roles of glucose metabolic reprogramming in chemo- and radio-resistance
10.1186/s13046-019-1214-z · 2019 · External reference
Role of p53 in breast cancer progression: An insight into p53 targeted therapy
10.7150/thno.81847 · 2023 · External reference
Synergistic Cytotoxicity of Renieramycin M and Doxorubicin in MCF-7 Breast Cancer Cells
10.3390/md17090536 · 2019 · External reference
Does denosumab offer survival benefits? -Our experience with denosumab in metastatic non-small cell lung cancer patients treated with immune-checkpoint inhibitors
10.21037/jtd-21-150 · 2021 · External reference
Efficacy and safety of concomitant immunotherapy and denosumab in patients with advanced non-small cell lung cancer carrying bone metastases: A retrospective chart review
10.3389/fimmu.2022.908436 · 2022 · External reference
Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer
10.1073/pnas.2117754119 · 2022 · External reference
Clearance of therapy-induced senescent tumor cells by the senolytic ABT-263 via interference with BCL-XL -BAX interaction
10.1002/1878-0261.12761 · 2020 · External reference
Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer
10.1016/j.surg.2005.06.016 · 2005 · External reference
Paclitaxel’s Mechanistic and Clinical Effects on Breast Cancer
10.3390/biom9120789 · 2019 · External reference
Lapatinib enhances paclitaxel toxicity in MCF-7, T47D, and MDA-MB-321 breast cancer cells
10.1016/j.tiv.2021.105200 · 2021 · External reference
Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin
10.1158/1078-0432.ccr-10-0503 · 2010 · External reference
Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models
10.1158/1535-7163.mct-08-0534 · 2009 · External reference
DrugCombDB: a comprehensive database of drug combinations toward the discovery of combinatorial therapy
2020 · External reference
An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies
10.1158/1535-7163.mct-15-0843 · 2016 · External reference
Network-based prediction of drug combinations
10.1038/s41467-019-09186-x · 2019 · External reference
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
10.1038/nature11003 · 2012 · External reference
